10,510 Shares in Rezolute, Inc. (NASDAQ:RZLT) Acquired by Jeppson Wealth Management LLC

Jeppson Wealth Management LLC bought a new position in shares of Rezolute, Inc. (NASDAQ:RZLT) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 10,510 shares of the company’s stock, valued at approximately $45,000.

Several other hedge funds and other institutional investors have also modified their holdings of RZLT. Affinity Asset Advisors LLC bought a new position in shares of Rezolute during the 1st quarter worth approximately $4,080,000. Rosalind Advisors Inc. bought a new position in Rezolute in the 1st quarter valued at $510,000. Vanguard Group Inc. raised its position in Rezolute by 10.4% in the 1st quarter. Vanguard Group Inc. now owns 1,553,352 shares of the company’s stock valued at $3,961,000 after purchasing an additional 145,700 shares during the last quarter. Acadian Asset Management LLC bought a new position in Rezolute in the 1st quarter valued at $229,000. Finally, Virtu Financial LLC bought a new position in Rezolute in the 1st quarter valued at $37,000. Institutional investors own 82.97% of the company’s stock.

Insider Buying and Selling

In related news, CFO Daron Evans acquired 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was acquired at an average cost of $4.04 per share, with a total value of $161,600.00. Following the completion of the purchase, the chief financial officer now directly owns 40,000 shares in the company, valued at $161,600. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders purchased a total of 49,115 shares of company stock valued at $198,395 over the last three months. Company insiders own 20.80% of the company’s stock.

Rezolute Stock Down 0.9 %

Shares of Rezolute stock traded down $0.04 during trading on Friday, reaching $4.33. 23,119 shares of the company were exchanged, compared to its average volume of 429,265. Rezolute, Inc. has a twelve month low of $0.72 and a twelve month high of $6.10. The business has a 50-day moving average price of $4.45 and a 200-day moving average price of $3.46. The firm has a market capitalization of $173.78 million, a price-to-earnings ratio of -3.83 and a beta of 1.18.

Analyst Ratings Changes

Several equities analysts have issued reports on RZLT shares. BTIG Research started coverage on Rezolute in a research report on Wednesday, July 17th. They issued a “buy” rating and a $13.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research report on Tuesday, August 6th. Craig Hallum started coverage on Rezolute in a research report on Tuesday, June 4th. They issued a “buy” rating and a $14.00 price objective for the company. Guggenheim started coverage on Rezolute in a research note on Tuesday, August 27th. They issued a “buy” rating and a $11.00 target price for the company. Finally, Maxim Group lifted their target price on Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $10.50.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.